EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ligilactobacillus salivarius CNCM I-4866, a potential probiotic candidate, shows anti-inflammatory properties in vitro and in vivo

Celia Carbonne, Sead Chadi, Camille Kropp, Lise Molimard, Florian Chain, Philippe Langella, Rebeca Martin

Frontiers in Microbiology · 29.11.2023 · 14

DOI: 10.3389/fmicb.2023.1270974 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 29.11.2023. Verfasst von Celia Carbonne und 6 weiteren Autor:innen. Beteiligte Einrichtung: Micalis Institute, AgroParisTech, INRAE, Université Paris-Saclay, Jouy-en-Josas, France. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aim of this work was to characterize a new strain of Ligilactobacillus salivarius (CNCM I-4866) (CNCM I-4866) to address its potential as probiotic with a special focus on intestinal inflammation. Potential anti-inflammatory abilities of this strain were evaluated through in vivo and in vitro experiments.

Methods

Firstly, the strain was tested in a murine acute inflammation colitis model induced by DNBS. In vitro characterization was then performed with diverse tests: modulation capability of intestinal permeability; study of the impact on immunity profile through cytokines dosage; capacity to inhibit pathogens and adhere to intestinal cells lines. Production of metabolites, antibiotic resistance and survival to gastro-intestinal tract conditions were also tested.

Results

In vitro assay has shown a reduction of colonic damage and markers of inflammation after treatment with CNCM I-4866. Transcriptomic analysis performed on colons showed the capacity of the strain to down-regulate pro-inflammatory cytokines. L. salivarius CNCM I-4866 exerted anti-inflammatory profile by reducing IL-8 production by TNF-α stimulated cell and modulated cytokines profile on peripheral blood mononuclear cells (PBMC). It protected intestinal integrity by increasing trans-epithelial electrical resistance (TEER) on Caco-2 TNF-α inflamed cells. Additionally, L. salivarius CNCM I-4866 displayed inhibition capacity on several intestinal pathogens and adhered to eukaryotic cells. Regarding safety and technical concerns, CNCM I-4866 was highly resistant to 0.3% of bile salts and produced mainly L-lactate. Finally, strain genomic characterization allowed us to confirm safety aspect of our strain, with no antibiotic gene resistance found.

Discussion

Taken together, these results indicate that L. salivarius CNCM I-4866 could be a good probiotic candidate for intestinal inflammation, especially with its steady anti-inflammatory profile.

Schlagwörter

Stichwörter der Autor:innen

DNBS inflammationLigilactobacillus salivariusanti-inflammatoryin vitroprobiotic

Autor:innen und Institutionen

  • Micalis Institute, AgroParisTech, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.

Zitieren

APA

Carbonne, C., Chadi, S., Kropp, C., Molimard, L., Chain, F., Langella, P., & Martin, R. (2023). Ligilactobacillus salivarius CNCM I-4866, a potential probiotic candidate, shows anti-inflammatory properties in vitro and in vivo. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1270974

Vancouver

Carbonne C, Chadi S, Kropp C, Molimard L, Chain F, Langella P, et al. Ligilactobacillus salivarius CNCM I-4866, a potential probiotic candidate, shows anti-inflammatory properties in vitro and in vivo. Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1270974

BibTeX
@article{Carbonne2023,
  author = {Carbonne, Celia and Chadi, Sead and Kropp, Camille and Molimard, Lise and Chain, Florian and Langella, Philippe and Martin, Rebeca},
  title = {Ligilactobacillus salivarius CNCM I-4866, a potential probiotic candidate, shows anti-inflammatory properties in vitro and in vivo},
  journal = {Frontiers in Microbiology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fmicb.2023.1270974}
}
Kostenlos starten →